Go Deep
JHS Svendgaard Laboratories Limited
JHS Svendgaard Laboratories Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,873 | -53.0 | 0.58 | 0.09 | 11.65 |
| Oct 2026 | 21,511 | -41.5 | 0.48 | 0.09 | 9.55 |
JHS Svendgaard Laboratories Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 303,805,000.0 | 326,957,000.0 | 232,678,000.0 | 222,771,000.0 |
| Net Profit | 10,904,000.0 | -35,686,000.0 | 7,889,000.0 | -1,977,000.0 |
| EPS | 0.1 | -0.4 | 0.1 | -0.0 |
JHS Svendgaard Laboratories Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 1,007,367,000.0 | 912,638,000.0 | 698,058,000.0 | 840,824,000.0 | — |
| Net Profit | -19,224,000.0 | -197,443,000.0 | -40,577,000.0 | -175,171,000.0 | — |
| EPS | -0.2 | -2.4 | -0.5 | -2.2 | — |
JHS Svendgaard Laboratories Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 2,152,166,000.0 | 2,011,804,000.0 | 1,970,544,000.0 | 2,282,273,000.0 | — |
| Total Liabilities | 405,495,000.0 | 284,532,000.0 | 271,704,000.0 | 543,867,000.0 | — |
| Total Equity | 1,746,671,000.0 | 1,727,272,000.0 | 1,698,840,000.0 | 1,738,406,000.0 | — |
Owes vs Owns
JHS Svendgaard Laboratories Limited owed ₹0.19 for every ₹1 it owned in Mar 2026, down from ₹0.24 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.19× | 0.14× | 0.14× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
JHS Svendgaard Laboratories Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 8.8%Receivables 7.8%Inventory 7.0%Fixed assets (tangible) 42.1%Intangible assets 1.2%Long-term investments 0.5%Other assets 32.5%
How it's funded — Mar 2026
Short-term debt 4.3%Long-term debt 2.6%Payables 8.3%Other liabilities 3.7%Shareholders' equity 81.2%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 19.0 | 19.5 | 5.1 | 37.7 |
| Receivables | 16.8 | 13.1 | 12.9 | 18.5 |
| Inventory | 15.2 | 11.9 | 12.6 | 13.0 |
| Fixed assets (tangible) | 90.6 | 87.0 | 87.8 | 72.8 |
| Intangible assets | 2.7 | 3.3 | 3.4 | 0.8 |
| Long-term investments | 1.1 | 0.0 | 0.0 | 0.0 |
| Other assets | 69.9 | 66.4 | 75.2 | 85.3 |
| Liabilities & equity | ||||
| Short-term debt | 9.3 | 4.5 | 3.4 | 0.1 |
| Long-term debt | 5.5 | 0.7 | 0.1 | 13.2 |
| Payables | 17.9 | 13.4 | 14.1 | 20.0 |
| Other liabilities | 7.9 | 9.9 | 9.5 | 21.1 |
| Shareholders' equity | 174.7 | 172.7 | 169.9 | 173.8 |
| Net tangible assets | 172.0 | 169.4 | 166.5 | 173.0 |
JHS Svendgaard Laboratories Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating Activities | -26,577,000.0 | -51,779,000.0 | -91,770,000.0 | 232,862,000.0 |
| Investing Activities | -116,769,000.0 | -202,526,000.0 | -211,409,000.0 | 96,770,000.0 |
| Financing Activities | 113,432,000.0 | 230,712,000.0 | 21,739,000.0 | -8,999,000.0 |